Han Bo, Wang Shuguo, Zhao Hongguo
Department of Hemotology, Qingdao Hiser Hospital Affiliated to Qingdao University Qingdao 266033, Shandong Province, China.
Department of Clinical Laboratory, The Affiliated Qingdao Municipal of Qingdao University Qingdao 266003, Shandong Province, China.
Int J Clin Exp Pathol. 2020 Jan 1;13(1):89-98. eCollection 2020.
Burkitt's lymphoma (BL) is a rare and highly aggressive B cell non-Hodgkin lymphoma. High toxicity of chemotherapy for BL treatment causes morbidity and mortality. Many miRNAs have been used as biomarkers for early detection or therapy targets for tumors. However, the roles of miR-21 and miR-155 in Burkitt's lymphoma remain unclear.
We collected 15 blood samples from patients with Burkitt's lymphoma and evaluated the expression of miR-21 and miR-155. Then, we knocked down miR-21 and miR-155 expression in Burkitt's lymphoma cell lines and assessed cell proliferation, cell cycle, and apoptosis. Furthermore, we detected the activation of PI3K/AKT pathway by qPCR and western blot. Finally, we predicted the target genes of miR-21 and miR-155 by publicly available databases.
The expression of miR-21 and miR-155 in blood samples from patients with Burkitt's lymphoma were significantly upregulated. Knockdown of miR-21 and miR-155 significantly suppressed cell proliferation, and resulted in S phase arrest and cell apoptosis. The knockdown of miR-21 and miR-155 inhibited the activation of the PI3K/AKT pathway. We found that the target genes of miR-21 and miR-155 were C1RL and TCAP.
miR-21 and miR-155 promote the progression of Burkitt's lymphoma through PI3K/AKT signaling by targeting C1RL and TCAP. Our findings will provide a novel biomarker and therapeutic strategies for Burkitt's lymphoma.
伯基特淋巴瘤（BL）是一种罕见且侵袭性很强的B细胞非霍奇金淋巴瘤。用于治疗BL的化疗药物毒性高，会导致发病和死亡。许多微小RNA（miRNA）已被用作肿瘤早期检测的生物标志物或治疗靶点。然而，miR-21和miR-155在伯基特淋巴瘤中的作用仍不清楚。
我们收集了15例伯基特淋巴瘤患者的血液样本，评估miR-21和miR-155的表达。然后，我们在伯基特淋巴瘤细胞系中敲低miR-21和miR-155的表达，并评估细胞增殖、细胞周期和细胞凋亡。此外，我们通过定量聚合酶链反应（qPCR）和蛋白质免疫印迹法检测PI3K/AKT信号通路的激活情况。最后，我们通过公开可用的数据库预测miR-21和miR-155的靶基因。
伯基特淋巴瘤患者血液样本中miR-21和miR-155的表达显著上调。敲低miR-21和miR-155可显著抑制细胞增殖，并导致S期阻滞和细胞凋亡。敲低miR-21和miR-155可抑制PI3K/AKT信号通路的激活。我们发现miR-21和miR-155的靶基因是C1RL和TCAP。
miR-21和miR-155通过靶向C1RL和TCAP，经PI3K/AKT信号通路促进伯基特淋巴瘤的进展。我们的研究结果将为伯基特淋巴瘤提供一种新的生物标志物和治疗策略。
